Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus
| Autor: | Alexandra H Mulder, Francis J Wilbrink, Kavish J. Bhansing, Aart H Mudde |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
business.industry Liraglutide Endocrinology Diabetes and Metabolism Insulin medicine.medical_treatment Disease duration Type 2 Diabetes Mellitus 030209 endocrinology & metabolism Retrospective cohort study General Medicine Type 2 diabetes 030204 cardiovascular system & hematology medicine.disease humanities 03 medical and health sciences 0302 clinical medicine Diabetes mellitus Internal medicine Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5] Internal Medicine medicine In patient business medicine.drug |
| Zdroj: | Journal of Diabetes Investigation, 9, 4, pp. 979-980 Journal of Diabetes Investigation, 9, 979-980 |
| ISSN: | 2040-1116 |
| DOI: | 10.1111/jdi.12857 |
| Popis: | Contains fulltext : 198072.pdf (Publisher’s version ) (Open Access) Comment on the article of Usui et al. Retrospective cohort study of obese patients with type 2 diabetes mellitus (n = 69) demonstrates that the glucose-lowering effect of liraglutide as add on therapy to insulin relies on the remaining beta-cell function in type 2 diabetes. Shorter disease duration implies a more favourable prognosis for response on instantaneous substitution of insulin with liraglutide (HR 2.39 (95% CI: 1.20-4.76). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |